NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
 Company Roche (Atezolizumab with gemcitabine and carboplatin) Patient/carer groups Action Bladder Cancer UK Black Health Agency for Equality Bladder and Bowel Community Bladder and Bowel UK Cancer 52 Cancer Black Care Cancer Equality Fight Bladder Cancer Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Pelican Cancer Foundation South Asian Health Foundation 	 <u>General</u> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee
 Specialised Healthcare Alliance Tenovus Cancer Care <u>Professional groups</u>	 <u>Comparator companies</u> Accord Healthcare (carboplatin, cisplatin, doxorubicin, gemcitabine, methotrexate)
 Association of Cancer Physicians British Association of Urological Nurses British Association of Urological Surgeons British Geriatrics Society British Gynaecological Cancer Society British Institute of Radiology British Psychosocial Oncology Society 	 Allergan (gemcitabine) Amgen (pegfilgrastim) Chugai Pharma (lenograstim) Concordia International (methotrexate) Hospira UK (carboplatin, cisplatin, gemcitabine, methotrexate, vinblastine) Janssen-Cilag (doxorubicin) Lilly UK (gemcitabine)

Final stakeholder list for the technology appraisal of Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206] Issue date: August 2020 Page 1 of 4

© National Institute for Health and Care Excellence 2020. All rights reserved.

Consultees	Commentators (no right to submit or appeal)
 British Society of Urogenital Radiology British Society of Urogynaecology British Uro-Oncology Group Cancer Research UK Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Urology Foundation Others Department of Health and Social Care NHS Greater Preston CCG NHS Hartlepool and Stockton-on-Tees CCG Welsh Government 	 Medac GmbH (doxorubicin, gemcitabine) Merck Sharp & Dohme (pembrolizumab) Nordic Pharma (methotrexate) Orion Pharma (methotrexate) Pfizer (doxorubicin, methotrexate, vinblastine) Rosemont Pharmaceuticals (methotrexate) Sandoz (cisplatin, methotrexate) Seacross Pharmaceuticals (doxorubicin) Sun Pharma (carboplatin, gemcitabine) Teva UK (doxorubicin, lipegfilgrastim, methotrexate) Therakind (methotrexate) Cochrane Urology Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Cancer Research Network National Institute for Health Research Leeds Institute of Cancer & Pathology Associated Public Health Groups Public Health England Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.